|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/09/20 Intellia Therapeutics, Inc. 8-K:2,8,9 1/09/20 11:209K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size 1: 8-K 8-K for Prelim 2019 Results and Press Release HTML 35K 2: EX-99.1 Miscellaneous Exhibit HTML 27K 9: R1 Document and Entity Information HTML 49K 7: XML IDEA XML File -- Filing Summary XML 11K 8: XML XBRL Instance -- ntla-8k_20200109_htm XML 15K 11: EXCEL IDEA Workbook of Financial Reports XLSX 6K 4: EX-101.LAB XBRL Labels -- ntla-20200109_lab XML 58K 5: EX-101.PRE XBRL Presentations -- ntla-20200109_pre XML 35K 3: EX-101.SCH XBRL Schema -- ntla-20200109 XSD 19K 6: JSON XBRL Instance as JSON Data -- MetaLinks 12± 19K 10: ZIP XBRL Zipped Folder -- 0001564590-20-000550-xbrl Zip 16K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i January 9, 2020
i INTELLIA THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
i Delaware |
i 36-4785571 |
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
i 40 Erie Street, i Suite 130 i Cambridge, i Massachusetts |
|
i 02139 |
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: i (857) i 285-6200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
i ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
i ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
i ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
i Common Stock (Par Value $0.0001) |
|
i NTLA |
|
i The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2019, Intellia Therapeutics, Inc. (the “Company”) announced on January 9, 2020, that it expects to report that it had approximately $284 million of cash, cash equivalents and marketable securities as of December 31, 2019.
The information contained in Item 2.02 of this Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of December 31, 2019 and its results of operations for the three months and year ended December 31, 2019. The audit of the Company’s consolidated financial statements for the year ended December 31, 2019 is ongoing and could result in changes to the information set forth above.
The information in this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On January 9, 2020, the Company issued a press release titled “Intellia Therapeutics Highlights Recent Progress and Anticipated 2020 Milestones.” A copy of the press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) The following exhibits are included in this report:
|
Exhibit Number |
|
Description |
|
|
|
|
|
99.1 |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
|
|
|
|
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Intellia Therapeutics, Inc. |
|
|
|
|
|
|
|
Date: January 9, 2020 |
|
By: |
/s/ John M. Leonard |
|
|
|
|
Name: John M. Leonard |
|
|
|
|
Title: Chief Executive Officer and President |
2
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 1/9/20 | |||
| 12/31/19 | 10-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/01/22 Intellia Therapeutics, Inc. 424B5 2:526K Donnelley … Solutions/FA 3/04/22 Intellia Therapeutics, Inc. 424B5 2:547K Donnelley … Solutions/FA 7/01/21 Intellia Therapeutics, Inc. 424B5 1:604K Donnelley … Solutions/FA 6/28/21 Intellia Therapeutics, Inc. 424B5 1:601K Donnelley … Solutions/FA 12/02/20 Intellia Therapeutics, Inc. 424B5 1:586K Donnelley … Solutions/FA 11/30/20 Intellia Therapeutics, Inc. 424B5 1:585K Donnelley … Solutions/FA 11/30/20 Intellia Therapeutics, Inc. S-3ASR 11/30/20 5:913K Donnelley … Solutions/FA |